Pharmacoeconomics applied to chronic hepatitis C

Brazilian Journal of Infectious Diseases

Volumn 10, Issue 1, 2006, Pages 51-54

  Tatsch, Fernando Franciosi ^a   Sette Jr , Hoel ^b   Vianna, Denizar ^c  

^a Roche   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Hepatitis C; Peginterferon alfa 2a; Pharmacoeconomic

Indexed keywords

INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

CHRONIC HEPATITIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE NEED; HEPATITIS C; HUMAN; MEDICAL TECHNOLOGY; PREVALENCE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SOCIOECONOMICS; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN;

EID: 33745103062     PISSN: 14138670     EISSN: 14138670     Source Type: Journal    
DOI: 10.1590/S1413-86702006000100010     Document Type: Review

References (14)

1. Kolbet G. Health Economics - General Issues. In: Kolbet G, Health Economics: An Introduction to Economic Evaluation. 2.ed. London: Office of Health Economics 2002;1:9-24.
2. Scherer F.M. The Pharmaceutical Industry - Prices and Progress. New England Journal of Medicine 2004;351:927-32.
3. Focaccia R., Conceiçao O.J.G. Sette H., et al. Estimated Prevalence of Viral Hepatitis in the General Population of the Municipality of São Paulo Measured by a Serologic Survey of a Stratified, Randomized and Residence-Based Population. Brazilian Journal of Infectious Desease 1998;2(6):269-84.
4. IBGE. Censo Demográfico 2000 - Resultados do universo. Available at http://www.ibge.gov.br, accessed on 28/nov/2004.
5. Kim W.R. The Burden of Hepatitis C in United States. Hepatology 2002;36:S30-S4.
6. Lauer GM.,Walker B.D. Hepatitis C Virus Infection. New England Journal of Medicine 2001;345:41-52.
7. Herrine S.K. Approach to the Patient with Chronic Hepatitis C Virus Infection. Annals of Internal Medicine 2002; 136:747-57.
8. Zeu Zem S. Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well? Annals of Internal Medicine 2004;140:370-81.
9. Meltzer M.I. Introduction to Health Economics for Physicians. Lancet 2001;358:993-98.
10. Strader D.B., Wright T, Thomas D.L., Seeff L.B. Diagnosis, Management and Treatment of Hepatitis C. Hepatology 2004;39:1147-71.
11. Manns M., Mchutchison J., Gordon S., et al. Peginterferon alfa-2b plus Ribavirin Compared with Interferon Alfa-2b plus Ribavirin for Initial Treatment of Chronic Hepatitis C: a Randomized Trial. Lancet 2001;358:958-65.
12. Fried M., Shiffman M.L., Reddy K.R., et al. Peginterferon Alfa-2a (40KD) plus Ribavirin for Chronic Hepatitis C Virus Infection. New England Journal of Medicine 2002;347:975-82.
13. Hadziyannis S., Sette H., Morgan T., et al. Peginterferon Alfa-2a (40KD) and Ribavirin Combination Therapy in Chronic Hepatitis C A Randomized Study of Treatment Duration and Ribavirin Dose. Annals of Internal Medicine 2004; 140:346-55.
14. Sullivan S.D., Jensen D.M., Bernstein D.E., et al. Cost Effectiveness of Combination Peginterferon Alfa-2a (40KD) and Ribavirin Compared With Interferon Alfa-2b and Ribavirin in Patients With Chronic Hepatitis C. American Journal of Gastroenterology 2004;99:1490-6.